Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-01-11
2005-01-11
LeGuyader, John L. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S091310, C435S455000, C536S023100, C536S024500
Reexamination Certificate
active
06841541
ABSTRACT:
The present invention provides novel anticode oligomers and methods of using them for controlling growth of cancer cells expressing the bcl-2 gene.
REFERENCES:
patent: 4806463 (1989-02-01), Goodchild
patent: 4999290 (1991-03-01), Lee
patent: 5015568 (1991-05-01), Tsujimoto et al.
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5149628 (1992-09-01), Croce
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5459251 (1995-10-01), Tsujimoto et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5734033 (1998-03-01), Reed
patent: 5831066 (1998-11-01), Reed
patent: 6040181 (2000-03-01), Reed
patent: WO 9427426 (1994-12-01), None
patent: WO 9508350 (1995-03-01), None
Jansen, B. et al. 1998 Nature Medicine, vol. 4, No. 2, pp. 232-234.*
Green et al. J. of Am. Coll. Surg. vol. 191, No. 1, Jun. 2000.□□□□□.*
Agrawal et al. Molecular Medicine Today, vol. 6, pp. 72-81, Feb. 2000.*
Ma et al., Biotechnology Annula Review, vol. 5, pp. 155-196, 2000.*
Bennett et al. “Pharmacology of Antisense Therapeutic Agents”, Chapter 2, from Methods in Molecular Medicine: Antisense Therapeutics, Ed. S. Agrawal, Humana Press Inc., Totowa, NJ, ISBN: 0_89603-305-8, 1996.*
Jen et al., Stem Cells, vol. 18, pp. 307-319, 2000.*
Andrea D. Branch, A good antisense molecule is hard to find, TIBS 23—Feb. 1998, pp. 45-50.*
W. Michael Flanagan et al., Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide, RESEARCH.*
Asseline U et al., Nucleic acid-binding molecules with high affinity and base sequence specificity: intercalating agents covalently linked to oligodeoxynucleotides. Proc Natl Acad Sci Jun. 1984;81(11):3297-301.
Aviv H, Leder P. Purification of biologically active globin messenger RNA by chromatography on oligothmidylic acid-cellulose. Proc Natl Acad Sci. Jun. 1972;69(6):1408-12.
Bishop JM. The molecular genetics of cancer. Science. Jan. 16, 1987;235(4786):305-11.
Blake KR, Murakami A, Miller PS. Inhibition of rabbit globin mRNA translation by sequence-specific oligodeoxyribonucleotides. Biochemistry. Oct. 22, 1985;24(22):6132-8.
Boutorin AS et al., Complementary addressed reagents carrying EDTA-FE(II) groups for directed cleavage of single-stranded nucleic acids. FEBS Lett. Jun. 1984;172(1):4346.
Chen CH, Sigman DS. Nuclease activity of 1,10-phenanthroline-copper: sequence-specific targeting. Proc Natl Acad Sci. Oct. 1986;83(19):7147-51.
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. Apr. 1987;162(1):156-9.
Chu BC, Orgel LE. Nonenzymatic sequence-specific cleavage of single-stranded DNA. Proc Natl Acad Sci Feb. 1985;82(4):963-7.
Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. Oct. 1994;9(10):3049-55.
Croce et al., Molecular Basis Of Human B and T Cell Neoplasia. Advance in Viral Oncology, 7:35-51, G. Klein (ed.), New York: Raven Press, 1987.
Haldar S, Beatty C, Tsujimoto Y, Croce CM. The bcl-2 gene encodes a novel G protein. Nature. Nov. 9, 1989;342(6246):195-8.
Holt JT et al., An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol. Feb. 1988;8(2):963-73.
Kern JA et al., Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms. J Clin Invest. Jan. 1988;81(1):237-44.
Kitada S et al., Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Research and Development, vol. No. 3, pp. Nos. 157-169, Summer 1993.
Kitada S et al., Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Research and Development, vol. No. 4, pp. Nos. 71-79, Summer 1994.
Knorre DG et al., Reactive oligonucleotide derivatives and sequence-specific modification of nucleic acids. Biochimie. Jul.-Aug. 1985;67(7-8):785-9.
Miller PS et al., A New approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression). Anticancer Drug Des. Oct. 1987;2(2):117-28.
Miyashita T et al., bcl-2 gene transfer in increase relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. Oct. 1, 1992;52(19):5407-11.
Miyashita T et al., Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. Jan. 1, 1993;81(1):151-7.
Morvan F et al., alpha-DNA. I. Synthesis, characterization by high field 1H-NMR, and base-pairing properties of the unnatural hexadeoxyribonucleotide alpha-[d(CpCpTpTpCpC)] with its complement beta-[d(GpGpApApGpG)]. Nucleic Acids Res. Jun. 25, 1986;14(12):5019-35.
Negrini M et al., Molecular analysis of mbcl-2: structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma. Cell. May 22, 1987;49(4):455-63.
Paoletti C. Anti-sense oligonucleotides as potential antitumour agents: prospective views and preliminary results. Anticancer Drug Des. Mar. 1988;2(4):325-31.
Reed JC et al. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 1994;5 Suppl 1:61-5.
Reed et al. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. Oct. 15, 1990;50(20):6565-70.
Reed et al. Suppression of interleukin 1 receptor acquisition by monoclonal antibodies recognizing the 50 KD protein associated with the sheep erythrocyte receptor on human T lymphocytes. J Immunol. Mar. 1985;134(3):1631-9.
Reed et al. Effect of wheat germ agglutinin on the interleukin pathway of human T lymphocyte activation. J Immunol. Jan. 1985;134(1):314-23.
Reed et al. Recombinant interleukin 2 regulates levels of c-myc mRNA in a cloned murine T lymphocyte. Mol Cell Biol. Dec. 1985;5(12):3361-8.
Reed et al. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: Synergy with MYC and inhibition by BCL2 antisense. Proc. Natl. Acad. Sci., 87:3660-3664 (1990).
Reed JC et al., Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science. Jun. 5, 1987;236(4806):1295-9.
Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. May, 15, 1988;48(10):2659-68.
Stein CA et al., Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. Apr. 25, 1988;16(8):3209-21.
Strasser A et al., bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell. Nov. 29, 1991;67(5):889-99.
Stull RA et al., Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharm Res. Apr. 1995;12(4):465-83.
Tsujimoto Y et al., Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci, Jul. 1986;83(14):5214-8.
Uhlmann, Eugen et al.“Antisense Oligonucleotides: A New Therapeutic Principle,” Chemical Reviews, vol. 90, No. 4, p. Nos. 544-584, Jun. 1990.
van den Elsen P et al., Isolation of cDNA clones encoding the 20K T3 glycoprotein of human T-cell receptor complex. Nature. Nov. 29-Dec. 5, 1984;312(5993):413-8.
Vlassov VV et al., Complementary addressed modification and cleavage of a single stranded DNA fragment with alkylating oligonucleotide derivatives. Nucleic Acids Res. May 27, 1986;14(10):4065-76.
Webb TR et al., Hybridization triggered cross-linking of deoxyoligonucleotides. Nucleic Acids Res. Oct. 10, 1986;14(19):7661-74.
Weiss A et al., Ligand-receptor interactions required for commitment to the activation of the interleukin 2 gene. J Immunol., Apr. 1, 1987;138(7):2169-76.
Wickstrom EL et al., Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted
LeGuyader John L.
The Trustees of the University of Pennsylvania
Zara J
LandOfFree
Regulation of BCL-2-gene expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulation of BCL-2-gene expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of BCL-2-gene expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3426196